Influence of treatments in multiple sclerosis disability: A cohort study

Multiple Sclerosis Journal

Volumn 21, Issue 4, 2015, Pages 433-441

  Cocco, Eleonora ^b   Sardu, Claudia ^a   Spinicci, Gabriella ^b   Musu, Luigina ^b   Massa, Rita ^b   Frau, Jessica ^b   Lorefice, Lorena ^b   Fenu, Giuseppe ^b   Coghe, Giancarlo ^b   Massole, Serenella ^b   Maioli, Maria Antonietta ^b   Piras, Rachele ^b   Melis, Marta ^b   Porcu, Gianluca ^b   Mamusa, Elena ^b   Carboni, Nicola ^b   Contu, Paolo ^a   Marrosu, Maria Giovanna ^a,b  

^a Territorial Department of Nephrology and Dialysis   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

disability; immunomodulant; immunosuppressant; Multiple sclerosis; treatment

Indexed keywords

IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; IMMUNOLOGIC FACTOR; AZATHIOPRINE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE; NATALIZUMAB;

ADULT; CLINICAL ASSESSMENT; COHORT ANALYSIS; DISABILITY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; REVIEW; RISK ASSESSMENT; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPORTIONAL HAZARDS MODEL; ARTICLE; RISK FACTOR; TREATMENT OUTCOME;

ADULT; COHORT STUDIES; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPORTIONAL HAZARDS MODELS;

EID: 84938485211     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514546788     Document Type: Review

References (35)

1. Dutta R, Trapp BD. Relapsing and progressive forms of multiple sclerosis: Insights from pathology. Curr Opin Neurol. 2014 ; 27: 271-278
2. Sorensen PS. New management algorithms in multiple sclerosis. Curr Opin Neurol. 2014 ; 27: 246-259
3. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology. 2001 ; 56: 1496-1504
4. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002 ; 59: 679-687
5. Compston A. Making progress on the natural history of multiple sclerosis. Brain. 2006 ; 129: 561-563
6. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain. 2003 ; 126: 770-782
7. Debouverie M, Pittion-Vouyovitch S, Louis S, et al. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol. 2008 ; 15: 916-921
8. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010 ; 133: 1900-1913
9. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: A geographically based study 10: Relapses and long-term disability. Brain. 2010 ; 133: 1914-1929
10. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol. 1983 ; 13: 227-231
11. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 ; 50: 121-127
12. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 ; 58: 840-846
13. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 ; 69: 292-302
14. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997 ; 120: 2059-2069
15. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 ; 46: 907-911
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452
17. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: A comparative study. Stat Med. 2004 ; 23: 2937-2960
18. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007 ; 16: 241-249
19. Cocco E, Sardu C, Massa R, et al. Epidemiology of multiple sclerosis in south-western Sardinia. Mult Scler. 2011 ; 17: 1282-1289
20. Cocco E, Sardu C, Pieroni E, et al. HLA-DRB1-DQB1 haplotypes confer susceptibility and resistance to multiple sclerosis in Sardinia. PLoS One. 2012 ; 7: e33972
21. Kister I, Chamot E, Bacon JH, et al. Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium. Mult Scler. 2011 ; 17: 725-733
22. Sormani MP, Tintorè M, Rovaris M, et al. Will Rogers phenomenon in multiple sclerosis. Ann Neurol. 2008 ; 64: 428-433
23. Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the natural history of multiple sclerosis. Neurology. 2010 ; 74: 2004-2015
24. Trojano M, Liguori M, Bosco Zimatore G, et al. Age-related disability in multiple sclerosis. Ann Neurol. 2002 ; 51: 475-480
25. Confavreux C, Vukusic S. Natural history of multiple sclerosis: A unifying concept. Brain. 2006 ; 129: 606-616
26. Stankoff B, Mrejen S, Tourbah A, et al. Age at onset determines the occurrence of the progressive phase of multiple sclerosis. Neurology. 2007 ; 68: 779-781
27. Goodin DS, Traboulsee A, Knappertz V, et al. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon ?-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012 ; 83: 282-287
28. Trojano M. Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis?. Neurology. 2007 ; 69: 1478-1479
29. Conway DS, Miller DM, O'Brien RG, et al. Long term benefit of multiple sclerosis treatment: An investigation using a novel data collection technique. Mult Scler. 2012 ; 18: 1617-1624
30. Bergamaschi R, Quaglini S, Tavazzi E, et al. Immunomodulatory therapies delay disease progression in multiple sclerosis. Mult Scler. :
31. Brown MG, Kirby S, Skedgel C, et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?. Neurology. 2007 ; 69: 1498-1507
32. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol. 2007 ; 61: 300-306
33. Veugelers PJ, Fisk JD, Brown MG, et al. Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: A longitudinal population-based evaluation. Mult Scler. 2009 ; 15: 1286-1294
34. Tedeholm H, Lycke J, Skoog B, et al. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler. 2013 ; 19: 765-774
35. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2012 ; 308: 247-256